Lamivudine
- Product NDC
- 70518-2067
- 11-digit product format
- 705182067
- Labeler code
- 70518
- Product ID
- 70518-2067_c5ea2393-cac4-dc3e-e053-2a95a90a8dab
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Lamivudine
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- REMEDYREPACK INC.
- Application
- ANDA090457
- Marketing category
- ANDA
- Marketing start
- 2019-05-08
- Marketing end
- 0000-00-00
- Substance
- LAMIVUDINE
- Active strength
- 150 mg/1
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2022-12-31
- Current FDA listing
- Historical FDA.report record
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 70518-2067-0 | 70518206700 | 30 TABLET, FILM COATED in 1 BLISTER PACK (70518-2067-0) | 2019-05-08 | 0000-00-00 | No | No | Current |